Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest New research presented at a major oncology conference suggests that GLP-1 weight-loss medications may significantly reduce the risk of developing or dying from certain cancers. Studies indicate a 30% lower likelihood of developing breast cancer and a 30% reduced risk of death from breast cancer when these drugs are added to standard treatment. Furthermore, patients on weight-loss drugs showed up to a 50% decreased risk of their cancer spreading.

• GLP-1 weight-loss drugs may reduce the risk of developing or dying from cancer by up to 30%.
• One study found a 30% lower incidence of breast cancer in women taking GLP-1 medications.
• Adding weight-loss drugs to standard breast cancer treatment was associated with a 30% reduction in mortality risk.
• Patients with breast, lung, bowel, or liver cancer on weight-loss drugs were 38%-50% less likely to develop advanced stages of the disease.
• Researchers are exploring GLP-1 medications as potential cancer prevention tools due to their effects on inflammation, metabolism, and appetite regulation.
• The exact mechanisms by which these drugs impact cancer risk are still under investigation, with further studies needed to clarify their role beyond weight loss.
• Some patients on GLP-1 medications report an improvement in side effects from other cancer treatments, such as hormone blockers.